Special Issue "Bioactive Compounds from Marine Fungi"

Quicklinks

A special issue of Marine Drugs (ISSN 1660-3397).

Deadline for manuscript submissions: closed (31 January 2013)

Special Issue Editor

Guest Editor
Prof. Dr. Johannes F. Imhoff
Marine Mikrobiologie, IFM-GEOMAR, Düsternbrooker Weg 20, D-24105 Kiel und Kieler Wirkstoff-Zentrum KiWiZ, Am Kiel-Kanal 44, 24106 Kiel, Germany
E-Mail: jimhoff@ifm-geomar.de
Phone: +0431/600-4450 / -4451
Fax: +0431-600-4452

Special Issue Information

Dear Colleagues,

Nature continues to be most important in the delivery of new drugs or lead structures and the oceans are important sources of structurally unique natural products. Among the biota from the oceans marine-derived fungi are an outstanding source for secondary metabolites, many of which have highly complex structures, making them difficult to be supplied economically via chemical synthesis.

Fungi derived from marine sources are considered to represent a huge reservoir of secondary metabolites, many of which are biologically active and are produced e.g. by multifunctional enzyme complexes such as polyketide synthases (PKS) and non-ribosomal peptide synthetases (NRPS). Marine fungi are highly potent producers of bioactive substances with antifungal, antibacterial, antiviral, cytotoxic and immunosuppressive activity. The various biological activities make them a valuable source for pharmaceutical applications.

From an ecological point of view fungal secondary metabolites may act specifically in interspecies interactions to protect the host and/or the producer against competitors and/or diseases. On the other hand, fungal metabolites are considered of great importance in the ecology of marine communities and the analysis of fungal genetics, fungal physiology and fungal natural compound profiles will be essential to understand the interrelationships between fungi and their environment.

In addition, the rapid progress in genomic information significantly stimulates the search for secondary metabolite producers and secondary metabolite biosynthesis. It greatly improves our knowledge on the potential of secondary metabolite production in fungi and already has demonstrated that fungi encode the genetic information for the biosynthesis of many as yet unknown compounds.

This is good reason to devote a special issue of Marine Drugs to the bioactive compounds from marine fungi.

Prof. Dr. Johannes F. Imhoff
Guest Editor

Submission

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed Open Access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs).

Keywords

  • marine fungi
  • fungal genomics
  • polyketide synthases
  • non-ribosomal peptide synthesis
  • antitumoral activity
  • antibiotic activity
  • fungal secondary metabolites
  • secondary metabolite biosynthesis
  • fungal secondary metabolites
  • fungal interactions
  • fungal drugs

Published Papers (9 papers)

Mar. Drugs 2013, 11(6), 2054-2068; doi:10.3390/md11062054
Received: 1 April 2013; in revised form: 10 May 2013 / Accepted: 14 May 2013 / Published: 10 June 2013
Show/Hide Abstract | Download PDF Full-text (540 KB) | View HTML Full-text | Download XML Full-text |  Supplementary Files

Mar. Drugs 2013, 11(4), 1409-1426; doi:10.3390/md11041409
Received: 24 January 2013; in revised form: 11 March 2013 / Accepted: 3 April 2013 / Published: 23 April 2013
Show/Hide Abstract | Download PDF Full-text (498 KB) | View HTML Full-text | Download XML Full-text |  Supplementary Files

Mar. Drugs 2013, 11(3), 800-816; doi:10.3390/md11030800
Received: 18 December 2012; in revised form: 17 January 2013 / Accepted: 6 February 2013 / Published: 12 March 2013
Show/Hide Abstract | Download PDF Full-text (615 KB) | View HTML Full-text | Download XML Full-text |  Supplementary Files

Mar. Drugs 2013, 11(2), 551-558; doi:10.3390/md11020551
Received: 21 January 2013; in revised form: 13 February 2013 / Accepted: 18 February 2013 / Published: 22 February 2013
Show/Hide Abstract | Download PDF Full-text (543 KB) | View HTML Full-text | Download XML Full-text |  Supplementary Files

Mar. Drugs 2013, 11(2), 504-522; doi:10.3390/md11020504
Received: 28 November 2012; in revised form: 22 January 2013 / Accepted: 31 January 2013 / Published: 18 February 2013
Show/Hide Abstract | Download PDF Full-text (1166 KB)

Mar. Drugs 2012, 10(12), 2912-2935; doi:10.3390/md10122912
Received: 9 November 2012; in revised form: 29 November 2012 / Accepted: 5 December 2012 / Published: 19 December 2012
Show/Hide Abstract | Download PDF Full-text (1010 KB) | View HTML Full-text | Download XML Full-text |  Supplementary Files
abstract graphic

Mar. Drugs 2011, 9(4), 561-585; doi:10.3390/md9040561
Received: 17 February 2011; in revised form: 1 March 2011 / Accepted: 25 March 2011 / Published: 6 April 2011
Show/Hide Abstract | Download PDF Full-text (496 KB) | View HTML Full-text | Download XML Full-text

Mar. Drugs 2011, 9(3), 294-306; doi:10.3390/md9030294
Received: 13 January 2011; in revised form: 11 February 2011 / Accepted: 24 February 2011 / Published: 25 February 2011
Show/Hide Abstract | Download PDF Full-text (183 KB) | View HTML Full-text | Download XML Full-text
abstract graphic

Mar. Drugs 2011, 9(1), 43-58; doi:10.3390/md9010043
Received: 8 November 2010; in revised form: 15 December 2010 / Accepted: 22 December 2010 / Published: 27 December 2010
Show/Hide Abstract | Download PDF Full-text (320 KB) | View HTML Full-text | Download XML Full-text

Last update: 10 October 2012

Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert